Table 2 Overall patient’s characteristics at the end of interventional phase
Overall | Groups | P | |||
|---|---|---|---|---|---|
Absent/low risk | Intermediate risk | High risk | |||
N | 368 | 166 | 128 | 23 | |
Age (years) | 70.4 ± 9.2 | 69.7 ± 9.8 | 71.2 ± 8.2 | 70.0 ± 11.7 | 0.43 |
Males (n, %) | 173 (47%) | 80 (42.8%) | 54 (42.2%) | 12 (52.2%) | 0.49 |
SBP (mmHg) | 130.9 ± 12.8 | 125.4 ± 7.3 | 135.3 ± 13.7 | 148.3 ± 11.5 | < 0.001 |
DBP (mmHg) | 78.4 ± 7.3 | 76.5 ± 5.2 | 79.2 ± 7.8 | 91.1 ± 5.0 | < 0.001 |
Serum creatinine (mg/dL) | 1.2 ± 0.6 | 1.2 ± 0.6 | 1.3 ± 0.7 | 1.3 ± 0.4 | 0.13 |
eGFR (mL/min/1.73m2) | 60.5 ± 22.7 | 63.3 ± 22.4 | 56.7 ± 22.9 | 56.4 ± 19.3 | 0.033 |
Albuminuria (mg/day) | 80 [26–180] | 100 [30–190] | 60 [18–150] | 94 [60–230] | 0.033 |
Hemoglobin (g/dL) | 12.9 ± 1.6 | 12.9 ± 1.5 | 12.6 ± 1.8 | 13.2 ± 1.5 | 0.13 |
Glycaemia (mg/dL) | 150.2 ± 42.0 | 139.4 ± 27.6 | 157.9 ± 42.9 | 169.4 ± 59.4 | < 0.001 |
HbA1c (%) | 7.2 ± 0.9 | 6.8 ± 0.6 | 7.4 ± 0.9 | 8.1 ± 0.8 | < 0.001 |
Total cholesterol (mg/dL) | 181.1 ± 32.1 | 166.6 ± 24.5 | 193.8 ± 30.6 | 222.0 ± 24.7 | < 0.001 |
HDL-cholesterol (mg/dL) | 44.4 ± 12.8 | 43.9 ± 9.8 | 44.9 ± 15.9 | 41.7 ± 7.2 | 0.50 |
LDL-cholesterol (mg/dL) | 110.4 ± 30.1 | 98.3 ± 25.9 | 119.7 ± 27.6 | 147.6 ± 21.5 | < 0.001 |
Triglycerides (mg/dL) | 143.4 ± 58.1 | 135.2 ± 50.0 | 146.3 ± 59.7 | 163.3 ± 42.5 | 0.030 |
Therapeutic goals | |||||
SBP < 130 mmHg (n, %) | 234 (67.2%) | 154 (92.8%) | 59 (46.1%) | 0 (0.0%) | – |
DBP < 80 mmHg (n, %) | 276 (79.3%) | 160 (96.4%) | 89 (69.5%) | 0 (0.0%) | – |
HbA1c < 7% (n, %) | 203 (56.9%) | 144 (86.7%) | 40 (31.3%) | 0 (0.0%) | – |
LDL < 100 mg/dL (n, %) | 131 (39.6%) | 102 (61.4%) | 22 (17.2%) | 0 (0.0%) | – |
Treatment arm* | < 0.001 | ||||
MT | 199 (54.1%) | 116 (58.3%) | 51 (25.6%) | 2 (1.0%) | |
SoC | 169 (45.9%) | 50 (29.6%) | 77 (45.6%) | 21 (12.4%) | |